Showing results (251-260 of 453) with videos related to
Sort By:
Pageof 46
European Journal of Cancer (Oxford, England : 1990)|July 30, 2010
A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: unplanned admissions as an early indicator of patient attritionAndre T Brunetto, Joo Ern Ang, David Olmos, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2023
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)Roberto Carmagnani Pestana, Justin T Moyers, Jason Roszik, et al.Journal for Immunotherapy of Cancer|November 18, 2025
Prognosis and treatment response stratification according to loss of proofreading (LOP) POLE variantsGiulia Maddalena, Fadl A Zeineddine, Saikat Chowdhury, et al.Journal of Hepatology|November 16, 2023
Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinomaTimothy P DiPeri, Ming Zhao, Kurt W Evans, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2011
Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trialsDavid Olmos, Richard D Baird, Timothy A Yap, et al.Scientific Reports|December 17, 2020
Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancerReham Abdel-Wahab, Timothy A Yap, Russell Madison, et al.The Oncologist|December 13, 2025
Phase I Study of Bevacizumab and Temsirolimus Combination Therapy in Advanced Malignancies: Safety, Efficacy, and Ovarian Cancer ExpansionSarina A Piha-Paul, Chieh Tseng, Emily Thompson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2015
Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal CancerOriol Arqués, Irene Chicote, Isabel Puig, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2014
A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumorsJordi Rodon, Hussein A Tawbi, Anne L Thomas, et al.Cancer Research Communications|December 21, 2023
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid MalignanciesVivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, et al.Pageof 46